Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Headlines

Roche, muscling into weight-loss drug race, advances obesity treatment to late-stage trial

Published by Global Banking and Finance Review

Posted on September 22, 2025

Featured image for article about Headlines

By Maggie Fick

LONDON (Reuters) -Swiss drugmaker Roche signalled its ambition to join Eli Lilly and Novo Nordisk at the top of the booming weight-loss market on Monday, as it advanced one of its experimental obesity drugs into a late-stage trial.

Shares were up 2.2% in afternoon trading, outperforming a broadly unchanged European healthcare index.

Roche's decision to begin a phase III trial of its experimental obesity drug CT-388 marks a major step in its push to break into the fast-growing obesity drug market that some analysts estimate will be worth $150 billion annually by the early 2030s.

Roche acquired this drug candidate in late 2023 when it acquired U.S. biotech firm Carmot Therapeutics in its first effort to challenge the dominant makers of weight-loss drugs Novo Nordisk and Eli Lilly.

Shares had jumped nearly 5% when it reported significant weight-loss results from an early-stage trial of this drug.

THREE DRUGS BEING TRIALLED COULD BE BLOCKBUSTERS

At an investor day in London, company executives laid out why they believed Roche could seize market share from Novo and Lilly, the first entrants to the obesity drug race, showing their understanding of the market's unique dynamics. This included the fact that much of it remains a cash-payer market, with patients paying out of pocket without insurance reimbursement.

Roche pharmaceutical division head Teresa Graham told investors the company planned to secure a strong entry to the lucrative obesity-drug market with competitive products by 2030.

It has six drug candidates in trials for the treatment of obesity and related conditions like type 2 diabetes and hypertension, which the company estimates could all be launched by 2030. Three of those drugs could become blockbusters with annual sales over $1 billion, she said.

"Our goal is to become a Top 3 player (in the obesity drug market), and I want you to know I'm serious about this goal," Graham said.

(Reporting by Maggie Fick; editing by Danilo Masoni, Louise Heavens and Bernadette Baum)